All In Biotech

Drug Trial Radar · NCT06413498

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

452

Actual

Start

Aug 23, 2024

Primary completion

Jul 2028

Study completion Jul 2031

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Arcellx, Inc.
First posted
May 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.

Conditions

  • Multiple Myeloma

Interventions

  • Anitocabtagene AutoleucelDrug

    A single infusion of CAR+ transduced autologous T cells

  • CyclophosphamideDrug

    Administered intravenously

  • FludarabineDrug

    Administered intravenously

  • PomalidomideDrug

    Tablet administered orally

  • BortezomibDrug

    Administered intravenously or subcutaneously

  • DexamethasoneDrug

    Tablet administered orally

  • DaratumumabDrug

    Administered intravenously or subcutaneously

  • CarfilzomibDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to 4 years
  2. Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 MonthsTime frame: Up to 9 months

Locations

117 sites in 15 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic Hospital

    Gilbert, Arizona

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • UC San Diego Moores Cancer Center

    San Diego, California

  • UCLA Hematology/Oncology (Bowyer Infusion Clinic)

    Santa Monica, California

  • Stanford Cancer Institute

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Sylvester Comprehensive Cancer Center

    Coral Gables, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta

    Newnan, Georgia

  • St. Luke's Cancer Institute

    Boise, Idaho

  • University of Illinois Hospital and Health Sciences System

    Chicago, Illinois

  • IU Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • Ochsner Clinical Foundation

    New Orleans, Louisiana

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Corewell Health - Lemmen-Holton Cancer Pavilion

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • New Mexico Cancer Research Alliance

    Albuquerque, New Mexico

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • Weill Cornell Medicine - New York Presbyterian Hosptial

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Novant Health Cancer Institute Hematology- Forsyth

    Winston-Salem, North Carolina

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Baptist Cancer Center

    Memphis, Tennessee

  • Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research

    Nashville, Tennessee

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.